Company bodies

Dr. Abhishek Mathur is a senior biopharmaceutical leader with nearly two decades of experience spanning drug discovery,
CMC development, and end-to-end commercialization of biologics, biosimilars, and advanced therapeutic modalities,
including multispecific antibodies and antibody–drug conjugates (ADCs). He has held scientific and executive leadership
roles across leading global organizations, including Amgen and Catalent Pharma Solutions, as well as emerging and
growth-stage companies such as Enzene Biosciences Ltd and Biolexis Pvt Ltd (a Strides company).
Throughout his career, Dr. Mathur has contributed to the development and launch of innovative and high-impact
therapeutics, combining deep technical expertise in cell culture, biochemistry, validation, and CMC with strategic
capabilities in innovation management and business leadership. In addition to his corporate leadership roles, he is engaged
in biopharma consulting and key advisory positions, based in Bengaluru, India.
Dr. Mathur holds a PhD in Biological Sciences from Northwestern University, an MBA in Finance and Global Business from
Duke University’s Fuqua School of Business, and a B.Tech. in Chemical Engineering from IIT Bombay, reflecting a strong
integration of scientific depth and global business acumen.

Dr. Firelli Alonso is a seasoned biotechnology and pharmaceutical leader with ~40 years of experience in biologics and
vaccine research, development, and manufacturing. She served most recently as Senior Director of External Supply and
Outsourcing in Worldwide Research & Development at Pfizer, Inc., where she led the BioTherapeutics and Vaccines
Outsourcing group, overseeing global outsourcing strategy, project and contract management, and technology transfer
to external partners.
With deep expertise in viral vaccine development, recombinant proteins, and cGMP biologics production, Dr. Alonso has
played a key role in shaping external manufacturing strategies for complex biological products. After retiring from Pfizer
in late 2023, she founded ConsultFi Biologics LLC, providing consulting services to biopharma companies on CDMO
selection and biologics outsourcing.
Dr. Alonso holds a Ph.D. in Microbiology/Virology from the University of Alabama at Birmingham and completed
postdoctoral research at leading U.S. infectious disease and cancer research institutions.

Lourdes Gonzalez-Novo is an experienced pharmaceutical and biotechnology executive with over 20 years of global
leadership in commercial strategy and business development. She most recently served as Chief Commercial Officer (CCO)
at Enzene Biosciences Ltd, where she oversaw the commercial positioning and growth of the company’s biosimilars
portfolio and CDMO services before departing the role.
Prior to Enzene, she held senior roles in business development and commercial leadership at major industry organisations,
including Recipharm, Syngene International, and IDT Biologika, bringing deep expertise in commercial strategy, market
expansion, and partnership development.
Ms. Gonzalez-Novo holds an MBA in International Business and Finance and a strong track record of driving growth in
complex pharmaceutical markets.

Jonas Skjodt Møller is a Danish biotechnology executive with extensive leadership and operational experience in the
biopharmaceutical sector. He served as Chief Executive Officer of Albumedix Ltd., a global life-science company specializing
in recombinant human albumin and bio-enabling technologies, where he helped drive innovation, operational growth and
strategic development following his appointment in 2020 after several years as Chief Operating Officer.
Before leading Albumedix, Jonas held diverse roles across the biopharmaceutical industry, including positions in research
& development, commercial planning and marketing at major life-science companies such as Novo Nordisk and
Novozymes. He also co-founded several biotech startups and international bio-entrepreneurship networks, underscoring
his broad industry engagement.
Jonas holds advanced academic credentials, including an M.Sc. from Aalborg University, an MBA from Copenhagen
Business School, and executive education from Harvard Law School, reflecting his deep commitment to both scientific and
business leadership.

Dr. Thomas Richter brings over a decade of experience in investment banking, during which he successfully advised on
numerous M&A transactions in the healthcare and life sciences sectors.
He subsequently held several Managing Director and CEO positions at CDMO and API companies in Germany and the
United States, where he was responsible for driving strategic growth initiatives and strengthening operational performance.
Most recently, he served as CEO of BSV BioScience GmbH and continues to support the company in an advisory capacity.
Dr. Richter also serves as Managing Director of BioPharma Translationsinstitut Dessau Forschungs GmbH (BTI), an
organization focused on initiating application-oriented research projects. Under his leadership, BTI has developed a
proprietary enzymatic technology platform for the manufacturing of antibody–drug conjugates (ADCs) and other complex
protein conjugates, further reinforcing his strong expertise at the intersection of innovation, advanced biologics
manufacturing and strategic business development.

Graduate of the John F. Kennedy School of Government (MPA) at Harvard University and Tufts University (BA) in the United States. Since March 2020, he has been the President of the Supervisory Board and a Partner in the consulting company Five Rand Sp. z o.o. In recent years, he has worked for PGE Polska Grupa Energetyczna S.A., Kulczyk Holding S.A., Euronet Worldwide, Inc., and Horton International, among others. In 1990-1995, he served as advisor to the Minister of Finance (from Leszek Balcerowicz to Grzegorz Kołodko) on the transformation and restructuring of the Polish financial services sector; he was also a member of the team negotiating the agreement with the London Club. Currently, he serves on the Supervisory Board of Platige Image S.A. Robert Koński meets the independence criteria referred to in Rule II.Z.4 of the document “Code of Best Practice for WSE Listed Companies 2021”.

Robert Koński has knowledge of accounting and auditing and is skilled in the industry in which Mabion operates.

Graduate of the Faculty of Law of the Jagiellonian University in Kraków. Legal Counselor. Managing Partner at InCorpore Banach Szczypiński Partners. He started his career at the Ministry of Finance and then worked for PricewaterhouseCoopers sp. z o.o. for several years, most recently as the leader of the Proceedings and International Tax Law team. Member of a number of supervisory boards of capital companies, including, among others, Chairman of the Supervisory Board of Poczta Polska S.A. and PHN S.A. For many years an expert of the Tax Council of the Polish Confederation of Private Employers Lewiatan, including acting Head of the Tax Council. Author of numerous publications in the field of law, including the commentary “Polskie umowy o unikaniu podwójnego opodatkowania” [Polish agreements on avoiding double taxation] published by CH Beck. He repeatedly represented parties in proceedings before administrative authorities and administrative and common courts, which ended with the client’s success. Józef Banach meets the independence criteria referred to in principle II.Z.4 of the document “Code of Best Practice for WSE Listed Companies 2021”.

Józef Banach has knowledge of accounting and auditing and is skilled in the industry in which Mabion operates.

Graduate of Harvard Law School (Master of Laws) and the Faculty of Law and Administration of the University of Warsaw (Master of Laws). He also completed the Georgetown Leadership Seminar at Georgetown University and the British Law Centre (University of Warsaw – University of Cambridge).
Mr. Mateusz Rosa-Gawałkiewicz has over 10 years of experience in the investment industry (private equity investments) and operational work (building the value of portfolio companies for investment funds, working with management boards in the implementation of development and recovery initiatives and performance monitoring). He has also worked in the field of strategy consulting at McKinsey and Company.
For several years, he has been involved in commercialising scientific innovations by creating and developing companies in the medical and biotech sectors.
At present: Investment Advisor at Twiti Investments Limited, Member of the Supervisory Board of Neuro Device Group S.A., Member of the Management Board of CBM 16 Sp. z o.o., Deputy President of the Management Board of the Transatlantic Future Leaders Forum.

Mr. Przemyslaw Mencel has 20 years of experience as CFO in the pharmaceutical, FMCG, consulting, construction, and IT industries, in both sales, service, and manufacturing organisations. At present, he holds the following positions: Group CFO at Twiti Investments Limited, CFO at Cellis Sp. z o.o., and CFO at Lipid Systems Sp. z o.o. Positions previously held by him include: 2021 – Group CFO at Eveline Cosmetics Group, 2019–2020: Interim Group CFO at Raisead Holding Group, 2012–2019: Group CFO at Cottonex Group, 2011–2012: Interim Executive at Telos Partners (PWB Awbud), 2007–2011: CFO at Grass Cavagna Group, 2001–2007: CFO at EGIS Pharmaceuticals (Servier Group). Mr. Przemysław Mencel also has over 7 years of practical experience in the EMEA region in directing and supervising the financial operations of businesses in several tax jurisdictions, as well as extensive experience in establishing internal procedures, processes, and controls. He holds an MBA from Georgia State University as well as AICPA-CIMA (CGMA, FCMA) and LCCI qualifications.

An expert in planning and implementing long-term sustainable strategies, he drives business decisions while preserving value, protecting assets, and seeking new opportunities for the organisation, and combining it at the same time with the ability to integrate financial and non-financial data to achieve a complete picture of the business. He has many years of experience in capital acquisition, risk management, internal control, value building, change management.

Graduate of the Faculty of Medicine at the Medical University of Lodz and Postgraduate Studies in Management Accounting at the University of Lodz. Licensed securities broker (license No. 449). Associated with the capital market since 1994. Worked for HSBC Securities Polska, Dom Maklerski BZ WBK, Santander Biuro Maklerskie where he was responsible for sales to institutional clients (investment funds, pension funds, asset management companies). He is competent in conducting transactions on the domestic and foreign cash and derivatives markets. He participated in the preparation and conduct of numerous public offerings of companies on the primary and secondary market. Since July 2020 he has been working for Polfarmex S.A.

Przemysław Mencel – Audit Committee Chairman

Józef Banach
Robert Koński